Clinical Trials for Evopoint Biosciences

Explore 9 clinical trials worldwide

Showing 1-9 of 9 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Evopoint Biosciences

Clinical Trials (9)

NCT06987500
A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment
PHASE1/PHASE2Recruiting
132 participants
Started: Apr 11, 2025 · Completed: Aug 16, 2027
1 condition2 sponsors1 location
NCT06776952
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
PHASE3Not yet recruiting
120 participants
Started: Feb 4, 2025 · Completed: Apr 30, 2028
1 condition1 sponsor0 locations
NCT06702605
To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
PHASE2Not yet recruiting
50 participants
Started: Nov 30, 2024 · Completed: Jan 31, 2027
1 condition1 sponsor0 locations
NCT06799637
Study of XNW28012 in Subjects with Advanced Solid Tumors Who Failed Standard Treatments
PHASE1/PHASE2Recruiting
200 participants
Started: Dec 1, 2023 · Completed: Dec 31, 2026
4 conditions1 sponsor24 locations
NCT06022757
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
PHASE1/PHASE2Recruiting
204 participants
Started: Sep 20, 2023 · Completed: Aug 31, 2028
8 conditions2 sponsors1 location
NCT06792435
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
PHASE1/PHASE2Recruiting
240 participants
Started: Jul 27, 2023 · Completed: Dec 31, 2025
7 conditions1 sponsor1 location
NCT06702995
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
PHASE1/PHASE2Recruiting
307 participants
Started: Apr 19, 2023 · Completed: Jul 19, 2026
2 conditions1 sponsor2 locations
NCT05204368
Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)
PHASE3Not yet recruiting
780 participants
Started: Mar 30, 2023 · Completed: Dec 31, 2025
1 condition1 sponsor1 location
NCT06558513
To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors
PHASE1/PHASE2Recruiting
176 participants
Started: Jul 5, 2021 · Completed: Dec 31, 2024
2 conditions4 sponsors1 location